Rockefeller Capital Management’s GSK GSK Stock Holding History

Rockefeller Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.94M	Sell	113,228 -15,567	-12%	-$823K	0.01%	895
2026 Q1	$7.11M	Buy	128,795 +12,547	+11%	+$680K	0.01%	790
2025 Q4	$5.7M	Buy	116,248 +39,140	+51%	+$1.83M	0.01%	836
2025 Q3	$3.33M	Sell	77,108 -3,312	-4%	-$129K	0.01%	965
2025 Q2	$3.09M	Sell	80,420 -167,059	-68%	-$6.38M	0.01%	946
2025 Q1	$9.59M	Sell	247,479 -88,352	-26%	-$3.23M	0.02%	577
2024 Q4	$11.4M	Sell	335,831 -23,398	-7%	-$842K	0.03%	520
2024 Q3	$14.7M	Sell	359,229 -2,006	-0.6%	-$82.1K	0.04%	427
2024 Q2	$13.9M	Buy	361,235 +10,182	+3%	+$428K	0.04%	414
2024 Q1	$15M	Sell	351,053 -9,719	-3%	-$401K	0.04%	401
2023 Q4	$13.4M	Sell	360,772 -150,471	-29%	-$5.4M	0.04%	382
2023 Q3	$18.5M	Buy	511,243 +80,919	+19%	+$2.87M	0.07%	277
2023 Q2	$15.3M	Buy	430,324 +38,378	+10%	+$1.38M	0.06%	339
2023 Q1	$13.9M	Sell	391,946 -57,026	-13%	-$2M	0.06%	349
2022 Q4	$15.8M	Buy	448,972 +28,093	+7%	+$936K	0.08%	274
2022 Q3	$12.4M	Buy	420,879 +128,179	+44%	+$4.86M	0.06%	303
2022 Q2	$15.9M	Buy	292,700 +94,497	+48%	+$5.22M	0.08%	244
2022 Q1	$10.8M	Buy	198,203 +9,901	+5%	+$538K	0.05%	343
2021 Q4	$10.4M	Buy	188,302 +19,256	+11%	+$1M	0.05%	343
2021 Q3	$8.07M	Buy	169,046 +17,742	+12%	+$891K	0.04%	354
2021 Q2	$7.53M	Buy	151,304 +43,570	+40%	+$2.09M	0.04%	349
2021 Q1	$4.8M	Buy	107,734 +8,864	+9%	+$402K	0.03%	379
2020 Q4	$4.55M	Sell	98,870 -2,149,552	-96%	-$98.7M	0.03%	344
2020 Q3	$106M	Sell	2,248,422 -8,881	-0.4%	-$445K	0.99%	16
2020 Q2	$115M	Sell	2,257,303 -798,200	-26%	-$41M	1.2%	13
2020 Q1	$145M	Buy	3,055,503 +3,035,456	+15,142%	+$162M	1.9%	10
2019 Q4	$1.18M	Buy	20,047 +746	+4%	+$41.5K	0.01%	422
2019 Q3	$1.03M	Buy	19,301 +1,229	+7%	+$63.2K	0.01%	385
2019 Q2	$904K	Buy	18,072 +10,922	+153%	+$548K	0.01%	355
2019 Q1	$373K	Buy	+7,150	New	+$357K	0.01%	517

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Rockefeller Capital Management's GSK Position: Q2 2026 in Review

Rockefeller Capital Management reduced its GSK (GSK) stake by 12% in Q2 2026, selling an estimated $823K and leaving 113,228 shares worth $5.94M. The position accounts for 0.01% of the portfolio, ranked #895.

Rockefeller Capital Management first reported a position in GSK in Q1 2019 and has held it in 30 quarters since. The position peaked at $145M in Q1 2020. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Rockefeller Capital Management held 113,228 shares of GSK worth $5.94M as of Q2 2026.
Rockefeller Capital Management sold 15,567 GSK shares in Q2 2026, an estimated $823K.
GSK made up 0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #895 holding.
Rockefeller Capital Management first reported a position in GSK in Q1 2019 and has held it in 30 quarters since.
Rockefeller Capital Management's GSK position peaked at $145M in Q1 2020.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.